Skip to main content
AkademIndex

Products

For developers

AkademBasesoonOpen API for the ecosystem
Latin
English
Article

Protective Potential of Sodium-Glucose Cotransporter 2 Inhibitors in Internal Medicine (Part 1)

Ashot AvagimyanIsfahan University of Medical Sciences; Patrice Lumumba Peoples’ Friendship University of RussiaMohammad SheibaniIran University of Medical SciencesА. И. ТрофименкоKuban State Medical UniversityEvgenii E. LysovKuban State Medical UniversityФарида Муиновна ХамидоваSamarkand State Medical UniversityAnahit Z. AznauryanYerevan State Medical University after M. HeratsiL. M. SukiasyanYerevan State Medical University after M. HeratsiKarmen SahakyanYerevan State Medical University after M. HeratsiTamara R. GevorgyanYerevan State Medical University after M. HeratsiMarina R. TatoyanYerevan State Medical University after M. HeratsiGayne MkrtchyanYerevan State Medical University after M. HeratsiGoharik L. MeltonyanYerevan State Medical University after M. HeratsiAnna R. PetrosyanYerevan State Medical University after M. HeratsiL. A. MartemyanovaGomel State Medical UniversityRuzanna PetrosyanLebanese American UniversityО. И. УразоваSiberian State Medical UniversityNana PogosovaPatrice Lumumba Peoples’ Friendship University of Russia; National Medical Research Centre of Cardiology named after Academician E.I. ChazovNizal SarrafzadeganIsfahan University of Medical Sciences
ABI

Abstract

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have emerged as a revolutionary class of drugs with far-reaching protective effects in multiple organs. The protective potential of SGLT2i is much broader than that of the classical concept of glucose control and consists of an entire conglomerate of associated pleiotropic effects. This study aims to provide a descriptive review of the pleiotropic therapeutic potential of SGLT2i. The first part of the literature review examined the use of SGLT2i in cardiology and nephrology. The use of SGLT2i represents an innovative approach to improving patients’ quality of life and course of heart failure and chronic kidney disease, regardless of left ventricular ejection fraction and type 2 diabetes.

Topics

Identifiers

Citations and references

Metrics — AkademScholar · Coming soon